Amgen (AMGN) reported Q4 EPS of $4.09, in-line with the analyst estimate of $4.09. Revenue for the quarter came in at $6.8 billion versus the consensus estimate of $6.74 billion.
GUIDANCE:
Amgen sees FY2023 EPS of $17.40-$18.60, versus the consensus of $18.33. Amgen sees FY2023 revenue of $26-27.2 billion, versus the consensus of $27.3 billion.